TY - JOUR
T1 - Current trends to design antimalarial drugs targeting N-myristoyltransferase
AU - Cavalcanti, Misael de Azevedo Teotônio
AU - Menezes , Karla Joane da Silva
AU - Viana, Jéssika de Oliveira
AU - Rios, Éric de Oliveira
AU - de Farias, Arthur Gabriel Corrêa
AU - Weber, Karen Cacilda
AU - Nogueira, Fátima
AU - Nascimento, Igor José dos Santos
AU - de Moura, Ricardo Olimpio
N1 - Funding Information:
The authors thank the Coordena\u00E7\u00E3o de Aperfei\u00E7oamento de Pessoal de N\u00EDvel Superior (CAPES), the National Council for Scientific and Technological Development (CNPq), and Funda\u00E7\u00E3o de Apoio \u00E0 Pesquisa do Estado da Para\u00EDba the National (FAPESQ) for their support to the Brazilian Postgraduate Programs. Additionally, thanks to the National Institute of Science and Technology on Molecular Sciences (INCT-CiMol), Grant CNPq 406804/2022-2 and Funda\u00E7\u00E3o para a Ci\u00EAncia e Tecnologia through projects GHTMUID/04413/2020 and LA-REAL-LA/P/0117/2020
Publisher Copyright:
© 2024 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Malaria is a disease caused by Plasmodium spp., of which Plasmodium falciparum and Plasmodium vivax are the most prevalent. Unfortunately, traditional and some current treatment regimens face growing protozoan resistance. Thus, searching for and exploring new drugs and targets is necessary. One of these is N-myristoyltransferase (NMT). This enzyme is responsible for the myristoylation of several protein substrates in eukaryotic cells, including Plasmodium spp., thus enabling the assembly of protein complexes and stabilization of protein–membrane interactions. Given the importance of this target in developing new antiparasitic drugs, this review aims to explore the recent advances in the design of antimalarial drugs to target Plasmodium NMT.
AB - Malaria is a disease caused by Plasmodium spp., of which Plasmodium falciparum and Plasmodium vivax are the most prevalent. Unfortunately, traditional and some current treatment regimens face growing protozoan resistance. Thus, searching for and exploring new drugs and targets is necessary. One of these is N-myristoyltransferase (NMT). This enzyme is responsible for the myristoylation of several protein substrates in eukaryotic cells, including Plasmodium spp., thus enabling the assembly of protein complexes and stabilization of protein–membrane interactions. Given the importance of this target in developing new antiparasitic drugs, this review aims to explore the recent advances in the design of antimalarial drugs to target Plasmodium NMT.
KW - antimalarial drugs
KW - antiparasitic drugs
KW - myristoyl-CoA
KW - neglected tropical diseases
KW - plasmodium falciparum
KW - quinoline
UR - http://www.scopus.com/inward/record.url?scp=85207491226&partnerID=8YFLogxK
U2 - 10.1080/17460913.2024.2412397
DO - 10.1080/17460913.2024.2412397
M3 - Review article
C2 - 39440556
AN - SCOPUS:85207491226
SN - 1746-0913
VL - 19
SP - 1601
EP - 1618
JO - Future Microbiology
JF - Future Microbiology
IS - 18
ER -
